Skip to main content
Shanghai Medicilon Inc. logo

Shanghai Medicilon Inc. — Investor Relations & Filings

Ticker · 688202 ISIN · CNE100003NQ8 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 817 across all filing types
Latest filing 2022-04-06 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688202

About Shanghai Medicilon Inc.

https://www.medicilon.com.cn/

Shanghai Medicilon Inc. is a comprehensive contract research organization providing integrated drug discovery and development services to the global pharmaceutical and biotechnology sectors. The company offers a full spectrum of preclinical services, including medicinal chemistry, lead optimization, in vitro and in vivo biology, pharmacology, and drug metabolism and pharmacokinetics (DMPK). Medicilon specializes in safety evaluation and toxicology studies conducted in GLP-compliant facilities to support Investigational New Drug (IND) applications. Its integrated platform facilitates the transition of drug candidates from initial discovery through preclinical development, covering both small molecule drugs and biologics. By leveraging advanced technology and scientific expertise, the company assists clients in accelerating drug development timelines and optimizing research outcomes.

Recent filings

Filing Released Lang Actions
美迪西：第三届董事会第四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the fourth meeting of the third board of directors of Shanghai Medicilon Inc. It includes multiple agenda items such as approval of the 2021 board work report, general manager work report, independent directors' report, audit committee report, financial results for 2021, profit distribution plan, appointment of auditors, remuneration plans, internal control evaluation report, amendments to board committee rules, credit facility applications, cash management plans, and social responsibility report. The document repeatedly states that these reports and detailed contents are published separately on the Shanghai Stock Exchange website and that these resolutions will be submitted to the shareholders' meeting for approval. The document itself does not contain the full annual report or financial statements but is a formal announcement of board meeting decisions and approvals related to the annual report and other reports. This fits the definition of Board/Management Information (MANG) as it announces board meeting resolutions and management reports approval. The document length is about 5,179 characters, which is consistent with a detailed board meeting announcement rather than a full annual report or financial report. Therefore, the correct classification is MANG with high confidence.
2022-04-06 Chinese
广发证券股份有限公司关于上海美迪西生物医药股份有限公司使用部分超募资金永久补充流动资金的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed opinion and verification report by a sponsoring securities firm regarding the use of part of the company's over-raised funds to permanently supplement working capital. It references regulatory guidelines, approval by the board and supervisory committee, and compliance with securities regulations. The content focuses on the management and use of raised funds, with no financial statements or earnings data presented. It is not an announcement of a report publication but a regulatory compliance and verification document related to capital use. This fits best under Capital/Financing Update (CAP), as it deals with the use of raised capital and fund management.
2022-04-06 Chinese
美迪西：立信会计师事务所（特殊普通合伙）2021年度内部控制审计报告
Regulatory Filings
2022-04-06 Chinese
美迪西：2021年度审计报告及财务报表
Regulatory Filings
2022-04-06 Chinese
美迪西：前次募集资金使用情况专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the usage of previously raised funds by Shanghai Medicilon Inc., including amounts raised, usage, management, investment projects, and economic benefits. It references regulatory requirements from the China Securities Regulatory Commission and includes financial figures and project details up to December 31, 2021. The content focuses on the actual use of capital raised from a prior fundraising event, consistent with a specialized report on capital usage. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is substantive and not merely an announcement or certification, so it is not RPA or RNS. Therefore, the correct classification is CAP.
2022-04-06 Chinese
美迪西：关于召开2021年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a notice about the convening of the 2021 Annual General Meeting (AGM) of Shanghai Medicilon Biopharmaceutical Co., Ltd. It includes details about the meeting date, voting methods, agenda items to be discussed and voted on, and instructions for shareholders. The document does not contain the actual annual report or financial statements but rather the notification and materials related to the AGM. The document length is 3611 characters, which is relatively short and consistent with an announcement or notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2022-04-06 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.